Commentary

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 285-291

  DiMasi, Joseph A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548305197     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1341     Document Type: Review

References (13)

1. Angell M. 2004. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. Random House: New York, NY.
2. Berndt ER, Danzon PM, Kruse GB. 2007. Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion. Managerial and Decision Economics 28(4/5): 229-248.
3. Berndt ER, Mortimer R, Bhattacharjya A, Parcee A. 2005. Authorized generic drugs, price competition and consumers' welfare. Working Paper. Available from URL: http://www.aei.org/events/eventID.1177,filter.all/ event_detail.asp [Accessed 24 April 2006].
4. Corrado CA, Hulten CR, Sischel DE. 2006. Intangible capital and economic growth. NBER Working Paper Series, Working Paper 11948 (http://www.nber.org/papers/w11948).
5. DiMasi JA. 2005. Comment on Me-Too Drugs: Is There a Problem? 1 March 2005. WHO, Commission on Intellectual Property Rights, Innovation and Public Health [CIPIH], Available from URL: http://www.who.int/intellectualproperty/ forum/dimasi_response/en/index.html [Accessed 24 April 2006].
6. DiMasi JA, Paquette C. 2004. The economics of follow-on drug development: trends in entry rates and the timing of development. PharmacoEconomics 22(Suppl 2): 1-14.
7. DiMasi JA, Paquette C. 2005. The economics of followon drug research and development: trends in entry rates and the timing of development-the authors reply. PharmacoEconomics 23(12): 1193-1202.
8. Ekelund M, Persson B. 2003. Pharmaceutical pricing in a regulated market. Review of Economics and Statistics 85(2): 298-306.
9. European Medicines Agency. 2004. EU standard of medicinal product registration: clinical evaluation of risk/benefit-the role of comparator studies. Doc. Ref: EMEA/19319/04, London, 21 October.
10. F-D-C Reports. 2004. CMS will focus on value, not price, of medicines, McClellan pledges. The Pink Sheet 66(13): 9-10.
11. F-D-C Reports. 2006. 'Authorized' generic study by FTC to be released in 2007. The Pink Sheet Daily.
12. Reiffen D, Ward MR. 2007. 'Branded Generics' as a strategy to limit cannibalization of pharmaceutical markets. Managerial and Decision Economics 28(4/5): 249-263.
13. Scherer FM. 2007. Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost. Managerial and Decision Economics 28(4/5): 265-281.